Irina Koffler | Investor Relations |
Spiro Rombotis | President and Chief Executive Officer |
Paul McBarron | Executive Vice President, Finance and Chief Operating Officer |
Mark Kirschbaum | Senior Vice President and Chief Medical Officer |
Jonathan Aschoff | ROTH MKM |
Ahu Demir | Ladenburg |
Jeff Jones | Oppenheimer |
Kemp Dolliver | Brookline Capital Markets |
Good afternoon and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call and Webcast. [Operator Instructions] Please note, today’s call is being recorded. I would now like to turn the call over to the company.
Good afternoon, everyone and thank you for joining today’s conference call to discuss Cyclacel’s financial results and business highlights for the fourth quarter and full year of 2022.
Before turning the call over to management, I would like to remind everyone that, during this conference call, forward-looking statements made by management are intended to fall within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 as amended.